Vigil Neuroscience Files Form 8-K: Completion of HSR Waiting Period for Merger with Sanofi

Strategic Insights -

Vigil Neuroscience, Inc., a Delaware corporation, has completed the Hart-Scott-Rodino Antitrust Improvements Act (HSR) waiting period, a critical milestone towards the merger with Sanofi. As of July 16, 2025, the HSR waiting period expired at 11:59 p.m., Eastern Time, allowing the companies to proceed with the merger. The completion of the merger remains subject to the satisfaction or waiver of other customary closing conditions specified in the Merger Agreement.

Key Takeaways:

  • Vigil Neuroscience, Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on July 17, 2025, announcing the completion of the HSR waiting period for the merger with Sanofi.
  • The HSR waiting period expired on July 16, 2025, at 11:59 p.m., Eastern Time, allowing the companies to proceed with the merger.
  • The completion of the merger is contingent upon the satisfaction or waiver of other customary closing conditions specified in the Merger Agreement, including the adoption of the Merger Agreement by Vigil's stockholders.
  • The special stockholder meeting to consider adoption of the Merger Agreement has been scheduled to be held virtually on August 4, 2025, at 8:30 a.m., Eastern Time.
  • As part of the merger, Vigil will become a wholly-owned subsidiary of Sanofi, with its product candidates, including iluzanebart and VG-3927, potentially benefiting from Sanofi's global reach and resources.
  • The merger is subject to regulatory approvals and potential risks, including the outcome of any legal proceedings that may be instituted against the parties and others related to the proposed transaction.

Statistics:

  • HSR waiting period: July 16, 2025, at 11:59 p.m., Eastern Time.
  • Special stockholder meeting: August 4, 2025, at 8:30 a.m., Eastern Time.
  • Merger completion: Subject to satisfaction or waiver of other customary closing conditions specified in the Merger Agreement, including the adoption of the Merger Agreement by Vigil's stockholders.
  • Number of shares: Vigil's common stock will become a wholly-owned subsidiary of Sanofi.

Sources:

1. Vigil Neuroscience, Inc., United States Securities and Exchange Commission, FORM 8-K, July 17, 2025.

2. Vigil Neuroscience, Inc., United States Securities and Exchange Commission, Annual Report on Form 10-K, 2024.